SAB Biotherapeutics (SABS) Amortizatization of Intangibles (2021 - 2026)
SAB Biotherapeutics (SABS) posted Amortizatization of Intangibles of $21705.0 for Q1 2026, down 8.15% on a QoQ basis from $23631.0 in Q4 2025, and little changed year-over-year from $21706.0 in Q1 2025.
SAB Biotherapeutics (SABS) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
SAB Biotherapeutics' Amortizatization of Intangibles history runs 6 years deep, the most recent figure standing at $21705.0 for Q1 2026.
- Quarterly Amortizatization of Intangibles changed 0.0% year-over-year to $21705.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $89336.0 (down 62.43% YoY) and the FY2025 annual result came in at $88631.0, down 62.62% from the prior year.
- Amortizatization of Intangibles was $21705.0 for Q1 2026 at SAB Biotherapeutics, down from $23631.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $172093.0 in Q4 2024 and bottomed at $21705.0 in Q1 2026.
- A 5-year average of $37256.3 and a median of $23631.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2024 — Amortizatization of Intangibles jumped 477.9% — and 2025, when it slumped 86.27%.
- SAB Biotherapeutics' Amortizatization of Intangibles stood at $24716.0 in 2022, then increased by 20.48% to $29779.0 in 2023, then soared by 477.9% to $172093.0 in 2024, then slumped by 86.27% to $23631.0 in 2025, then declined by 8.15% to $21705.0 in 2026.
- Business Quant data shows SABS's Amortizatization of Intangibles at $21705.0 in Q1 2026, $23631.0 in Q4 2025, and $22000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | SAB Biotherapeutics | 185.85 Mn | 185.85 Mn | - | 21,705.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21,705.00 |
| Mar 31, 2026 | 21,705.00 |
| Dec 31, 2025 | 23,631.00 |
| Dec 31, 2025 | 23,631.00 |
| Sep 30, 2025 | 22,000.00 |
| Sep 30, 2025 | 22,000.00 |
| Jun 30, 2025 | 22,000.00 |
| Jun 30, 2025 | 22,000.00 |
| Mar 31, 2025 | 21,706.00 |
| Mar 31, 2025 | 21,706.00 |
| Dec 31, 2024 | 172,093.00 |
| Dec 31, 2024 | 172,093.00 |
| Sep 30, 2024 | 22,000.00 |
| Sep 30, 2024 | 22,000.00 |
| Jun 30, 2024 | 22,000.00 |
| Jun 30, 2024 | 22,000.00 |
| Mar 31, 2024 | 83,994.00 |
| Mar 31, 2024 | 83,994.00 |
| Dec 31, 2023 | 29,779.00 |
| Dec 31, 2023 | 29,779.00 |